Table 1.
Descriptive statistics of patient characteristics.
| Categorical variable | N (%) | Continuous variable | Mean ± SD, Median (Min, Max) | N | |
|---|---|---|---|---|---|
| Gender | Male | 82 (60.3%) | Age (years) | 53.27 ± 17.68, 56.16 (17.86, 84.77) | 136 |
| Female | 54 (39.7%) | Weight (kg) | 77.54 ± 19, 75.8 (43.6, 134.5) | 136 | |
| Race | White | 82 (60.3%) | Height (cm) | 169.76 ± 13.24, 170.1 (76, 196) | 136 |
| Hispanic | 18 (13.2%) | BMI (kg/m2) | 27.67 ± 13.42, 26.27 (16.73, 165) | 136 | |
| African American | 19 (14%) | BSA (m2) | 1.89 ± 0.25, 1.89 (1.4, 2.51) | 136 | |
| Other | 17 (12.5%) | Troponin I (ng/mL) | 6.36 ± 50.15, 0.03 (0, 492) | 103 | |
| Cancer type | Solid | 42 (30.9%) | Troponin T (ng/mL) | 21.13 ± 14.56, 19.5 (6, 43) | 8 |
| Hematologic | 98 (69.1%) | BNP (pg/mL) | 509.05 ± 847.69, 241 (1.49, 5,479) | 101 | |
| Primary cancer | Breast | 4 (2.9%) | NT-proBNP (pg/mL) | 737 ± 523.03, 650 (212, 1,582) | 7 |
| Gastrointestinal | 7 (5.1%) | Serum creatinine (mg/dL) | 1.23 ± 1.11, 0.94 (0.3, 10.63) | 136 | |
| Genitourinary | 3 (2.2%) | WBC (cells/mL3) | 5.51 ± 6.69, 3.55 (0, 41) | 136 | |
| Gynecologic | 4 (2.9%) | Hemoglobin (g/dL) | 9.48 ± 1.65, 9.1 (6.7, 14.6) | 136 | |
| Head and Neck | 1 (0.7%) | pRBC administered within 24 h (units) | 0.21 ± 0.49, 0 (0, 2) | 23 | |
| Leukemia | 65 (47.8%) | Platelet count (day 0) (K/mL) | 64.46 ± 45.07, 51 (6, 147) | 136 | |
| Lung | 16 (11.8%) | Grade 1 (75–149 × 103 cells/μL) | 55 | ||
| Lymphoma | 29 (21.3%) | Grade 2 (50–74 × 103 cells/μL) | 14 | ||
| Melanoma | 1 (0.7%) | Grade 3 (25-49 × 103 cells/μL) | 33 | ||
| Renal | 1 (0.7%) | Grade 4 (0–24 × 103 cells/μL) | 34 | ||
| Sarcoma | 4 (2.9%) | Platelet administered within 24 h (units) | 1.57 ± 3.42, 0 (0, 23) | 37 | |
| Thymus | 1 (0.7%) | INR | 1.31 ± 0.28, 1.26 (0.87, 3.05) | 136 | |
| Advanced cancer | 105 (77.2%) | LVEF (%) by TTE | 55.23 ± 9.37, 55 (25, 70) | 136 | |
| History of radiotherapy | 44 (32.4%) | ||||
| Chemotherapy within 1 month | 92 (67.6%) | ||||
| Tobacco smoker within 1 year | 41 (30.1%) | ||||
| Hypertension | 57 (41.9%) | ||||
| Dyslipidemia | 87 (64%) | ||||
| Chronic lung disease | 13 (9.6%) | ||||
| Diabetes mellitus | 15 (11%) | ||||
| CKD, dialysis-dependent | 2 (1.5%) | ||||
| Cerebrovascular disease | 7 (5.1%) | ||||
| Coronary artery disease | 6 (4.4%) | ||||
| Chronic heart failure | 12 (12.6%) | ||||
| Family history premature CAD | 8 (5.9%) | ||||
| Aspirin use only | 14 (10.3%) | ||||
| Clopidogrel use only | 3 (2.2%) | ||||
| DOAC use only | 9 (6.6%) | ||||
| Platelet transfusion refractoriness | 27 (19.9%) | ||||
| Cardiac tamponade on TTE | 68 (50%) | ||||
| Complications | 5 (3.7%) | ||||
| Procedural guidance modality | Echocardiogram | 131 (96.3%) | |||
| Fluoroscopy | 61 (44.9%) | ||||
| Combined | 96 (70.6%) | ||||
| Aspirated fluid appearance | Serous | 57 (41.9%) | |||
| Hemorrhagic | 79 (58.1%) | ||||
| Malignant aspirated fluid | 56 (41.2%) |
CKD, chronic kidney disease; CAD, coronary artery disease; DOAC, direct oral anticoagulant; TTE, transthoracic echocardiogram.